Morgan Stanley reaffirmed their overweight rating on shares of LONZA GRP AG/ADR (OTCMKTS:LZAGY) in a report released on Monday, The Fly reports.
Several other research firms also recently commented on LZAGY. Societe Generale restated a buy rating on shares of LONZA GRP AG/ADR in a research report on Friday, September 4th. Zacks Investment Research downgraded LONZA GRP AG/ADR from a buy rating to a hold rating in a research report on Wednesday, August 19th. UBS Group restated a neutral rating on shares of LONZA GRP AG/ADR in a research report on Wednesday, July 8th. Finally, Credit Suisse Group reiterated an outperform rating on shares of LONZA GRP AG/ADR in a research report on Thursday, August 13th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $68.00.
LONZA GRP AG/ADR stock opened at $61.09 on Monday. The company has a market capitalization of $45.49 billion, a PE ratio of 44.59 and a beta of 0.79. LONZA GRP AG/ADR has a one year low of $31.93 and a one year high of $63.56. The business has a 50 day simple moving average of $61.33 and a 200 day simple moving average of $50.20.
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system.
Read More: Golden Cross
Receive News & Ratings for LONZA GRP AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LONZA GRP AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.